No abstract available.
Animals ; Ischemia* ; Kidney* ; Rats* ; Reperfusion*

A case of isolated Crohn's disease of appendix is reported. It is a rare disease which commonly mimics the symptoms of acute appendicitis. Review of 221 identical cases previously reported in the world literature revealed slight male predominance(1.17:1) and peak age of incidence in the third decade(24.3 yrs). In contrast to typical Crohn's disease, the rate of postoperative fistula and recurrence was minimal; 1.0% and 3.8%, respectively. Due to these differences, many consider it to be a separate disease entity from Crohn, and a new diagnostic term - "Idiopathic Granulomatous Appendicitis" - has gained wide acceptance in recent years.
Appendicitis* ; Appendix* ; Crohn Disease* ; Fistula ; Humans ; Incidence ; Male ; Rare Diseases ; Recurrence

No abstract available.
Humans ; Pregnancy, Twin* ; Twins*

Endometriosis in the abdominal wall following Cesarean section is one of the very rare condition among the extrapelvic endometriosis. Although benign, endometriosis possesses the unique ability to invade tissue and to disseminate or metastasize by hematogeneous, lymphatic route, or direct implantation. We reported the case with brief review of the literature.
Abdominal Wall* ; Cesarean Section* ; Endometriosis* ; Female ; Pregnancy

Purpose: To evaluate the proportion of bevacizumab and the reason for its usage in wet age-related macular degeneration (AMD). Methods: Retrospective analysis of medical records was performed for 1,541 patients who received ranibizumab, aflibercept, or bevacizumab injection to treat wet AMD. The proportion of bevacizumab among the entire set of injections was identified. The reason for selecting bevacizumab was additionally identified. Results: During the study period, a total of 2,929 anti-vascular endothelial growth factor (anti-VEGF) injections were performed; 2,236 (76.3%) were ranibizumab or aflibercept injections and 693 (23.7%) were bevacizumab injections. The most common reason for bevacizumab usage was ‘having a 0.1 or worse best-corrected visual acuity or being unable to assure reimbursement due to the development of extensive scarring or geographic atrophy’ (297 bevacizumab injections, 42.9%). The second most common reason was ‘the inability to assure reimbursement such as extrafoveal choroidal neovascularization (CNV) or early CNV without definite fluid in the foveal region’ (201 bevacizumab injections, 29.0%). Conclusions Bevacizumab was used in 23.7% of the anti-VEGF injections to treat wet AMD. When analyzing patients’ treatment burden and financial impact, the results of the present study may provide useful information. Further multi-center studies are required to evaluate more precisely the usage of anti-VEGF drugs.

Purpose: To evaluate the proportion of bevacizumab and the reason for its usage in wet age-related macular degeneration (AMD). Methods: Retrospective analysis of medical records was performed for 1,541 patients who received ranibizumab, aflibercept, or bevacizumab injection to treat wet AMD. The proportion of bevacizumab among the entire set of injections was identified. The reason for selecting bevacizumab was additionally identified. Results: During the study period, a total of 2,929 anti-vascular endothelial growth factor (anti-VEGF) injections were performed; 2,236 (76.3%) were ranibizumab or aflibercept injections and 693 (23.7%) were bevacizumab injections. The most common reason for bevacizumab usage was ‘having a 0.1 or worse best-corrected visual acuity or being unable to assure reimbursement due to the development of extensive scarring or geographic atrophy’ (297 bevacizumab injections, 42.9%). The second most common reason was ‘the inability to assure reimbursement such as extrafoveal choroidal neovascularization (CNV) or early CNV without definite fluid in the foveal region’ (201 bevacizumab injections, 29.0%). Conclusions Bevacizumab was used in 23.7% of the anti-VEGF injections to treat wet AMD. When analyzing patients’ treatment burden and financial impact, the results of the present study may provide useful information. Further multi-center studies are required to evaluate more precisely the usage of anti-VEGF drugs.

No abstract available.
Adenocarcinoma* ; Female ; Ovary*

The author surveyed on the ration of central serous retinopathy (C.S.R.) cases among total out patient, distribution of sex, distribution of age, sites of affected eye, and visual acuity in 271 cases of central serous retinopathy from March, 1973 to April, 1977. Fluorescein angiography was performed in 71 cases among them. Leakages of fluorescein were analysed by pictures. The results are obtained as follows: 1. The eyes of C.S.R. were observed in 0.75% among total out patients. 2. As to the distribution of sex, male were observed in 71.4%. 3. Among 271 cases, Unilateral affected cases (83.4%), and there were no difference between right and left eyes. 4. As to the distribution of age, 4-th decade were most frequently affected in 35.4%. 5. The cases were classified by leaking pattern as followings; Type I: Leaking was unremarkable. Type II: Leaking point appeared at early arterial phase and fades out gradually. Type III: Learking point appeared at early arterial phase and increased in density gradually, but the size of leaking area wes not enlarged. Type IVa: Leaking point appeared at early arterial phase and increase concentrically in the density and size. Type IVb: Leaking point appeared at early arterial phase and increased vertically (mushroom-shaped) in its size and density. 6. Type IVa in leaking pattern was most frequently observed. 7. A single leakage was found in 39.5% of all cases. 8. The leakages of fluorescein were found most frequently in the upper area particullary in the upper nasal area of the macula.
Central Serous Chorioretinopathy* ; Fluorescein ; Fluorescein Angiography ; Humans ; Male ; Outpatients ; Visual Acuity

Childhood asymmetry labium majus enlargement (CALME) is a disctinctive clinicopathologic entity of pre- and early puberty first described in 2005. It is defined as an expansion of normal soft tissues of the vulva. Although CALME is not a rare lesion, it has been called lipoma, fibroma, hamartoma, and fibrous hyperplasia. CALME is not a true neoplasm and is a physiologic growth in response to hormone. It may tend to resolve spontaneously and recur after surgical resection. We report four cases of CALME with a review of the literature. To the best of the knowledge, this is the first Korean report.
Child ; Fibroma ; Hamartoma ; Humans ; Hyperplasia ; Hypertrophy ; Lipoma ; Puberty ; Vulva

The placements of silicone tube and silicone stent are helpful in maintaining the patency of lacrimal passage in endoscopic intranasal dacryocystorhinostomy(DCR). Hwoever, they can cause obstruction of internal ostium due to complications, such as inflammation and granuloma formation. The authors evaluated the rates of granuloma formation in 33 cases who had undergone endoscopic DCR with placement of silicone tube and silicone stent and the optimal removal timing to increase patency rates. Granuloma formation was noted in 19 of 33 cases; 12 of the 19 cases developed granuloma formation between 7 and 12 week after operation. Therefore, we concluded that the rates of granuloma formation were higher in placement of both silicone tube and silicone stent than those of silicone tube alone, and the optimal time for their removal seemed to be between 4 and 6 weeks postoperatively.
Dacryocystorhinostomy* ; Granuloma* ; Inflammation ; Silicones* ; Stents*